Business, energy, technology, markets and global industry news from Business News Today

EULAR 2026

PharmaDeviceNews EULAR 2026
Representative image of immunology research and clinical trial analysis, reflecting Johnson & Johnson’s growing nipocalimab strategy in lupus and Sjögren’s disease.
Pharma & Biotech

Why Johnson & Johnson’s lupus and Sjögren’s data matter beyond one Phase 2 readout

See how Johnson & Johnson’s nipocalimab data could reshape lupus and Sjögren’s disease treatment strategy today!

Read More
Representative image: Biomedical researchers analyse immune-cell data in a laboratory setting, reflecting the scientific focus behind Antengene’s ATG-207 preclinical autoimmune therapy program and its CD3 and TGF-beta fusion approach.
Pharma & Biotech

Antengene brings first ATG-207 preclinical data to EULAR 2026 as autoimmune focus deepens

Find out how Antengene’s ATG-207 data could shape autoimmune drug development as CD3 and TGF-beta fusion biology enters focus.

Read More